Blog
RSS FeedPosted by Michael Wonder on 21 Dec 2022
FDA approves Genentech’s Actemra for the treatment of COVID-19 in hospitalised adults
21 December 2022 - Actemra is the first FDA approved monoclonal antibody to treat COVID-19. ...
Posted by Michael Wonder on 21 Dec 2022
Sanofi Pasteur COVID-19 vaccine authorised by MHRA
21 December 2022 - VidPrevtyn Beta, the COVID-19 vaccine developed by Sanofi, has been authorised by the MHRA. ...
Posted by Michael Wonder on 20 Dec 2022
ICER provides update on value based pricing of Paxlovid as an outpatient treatment for COVID-19
20 December 2022 - New data suggests Paxlovid will achieve common thresholds of cost effectiveness if priced between $563-$906 per treatment ...
Posted by Michael Wonder on 20 Dec 2022
COVID-19 vaccine safety report (15 December 2022)
15 December 2022 - To 11 December 2022, the TGA has received 706 reports which have been assessed as likely to ...
Posted by Michael Wonder on 19 Dec 2022
New report indicates COVID-19 vaccines saved Australia’s economy
19 December 2022 - Medicines Australia welcomes the latest peer-reviewed research paper indicating the rollout of the COVID-19 vaccinations significantly ...
Posted by Michael Wonder on 10 Dec 2022
Health Canada authorises the Pfizer-BioNTech Omicron BA.4/BA.5 bivalent adapted COVID-19 booster for children 5 to 11 years of age
9 December 2022 - Today, Health Canada authorised the Pfizer-BioNTech Comirnaty Omicron BA.4/BA.5 bivalent adapted booster for use in children 5 ...
Posted by Michael Wonder on 10 Dec 2022
Pfizer and BioNTech receive US FDA fast track designation for single dose mRNA based vaccine candidate against COVID-19 and influenza
9 December 2022 - Pfizer and BioNTech today announced the companies have received fast track designation from the US FDA ...
Posted by Michael Wonder on 08 Dec 2022
FDA authorises updated (bivalent) COVID-19 vaccines for children down to 6 months of age
8 December 2022 - Today, the US FDA amended the emergency use authorisations of the updated (bivalent) Moderna and Pfizer-BioNTech COVID-19 ...
Posted by Michael Wonder on 07 Dec 2022
US backs delay to decision on COVID patent waiver extension
6 December 2022 - The United States on Tuesday urged delaying a decision on whether to waive patent protection for ...
Posted by Michael Wonder on 07 Dec 2022
Updated eligibility for COVID-19 oral treatment
7 December 2022 - COVID-19 treatments can be taken in your own home and can help reduce your symptoms. ...
Posted by Michael Wonder on 07 Dec 2022
Novavax Nuvaxovid COVID-19 vaccine approved in Canada for use as a primary series in adolescents
7 December 2022 - Novavax today announced that Health Canada has approved a supplement to a new drug submission for Nuvaxovid ...
Posted by Michael Wonder on 07 Dec 2022
ETF concludes that bivalent original/Omicron BA.4-5 mRNA vaccines may be used for primary vaccination
6 December 2022 - EMA’s Emergency Task Force considers that adapted mRNA bivalent vaccines targeting the original strain and Omicron ...
Posted by Michael Wonder on 06 Dec 2022
Molnupiravir ‘effective Covid-19 anti-viral’: acting CMO Michael Kidd
6 December 2022 - Acting chief medical officer Michael Kidd has contradicted the nation’s top advisers on Covid-19 treatments on ...
Posted by Michael Wonder on 06 Dec 2022
Pfizer and BioNTech submit application to US FDA for emergency use authorisation of Omicron BA.4/BA.5 adapted bivalent COVID-19 vaccine in children under 5 years
5 December 2022 - Pfizer andBioNTech today announced that the companies have submitted an application to the US FDA for ...
Posted by Michael Wonder on 04 Dec 2022
Anti-viral COVID-19 treatment now available in the Netherlands for 1,250 Euros
1 December 2022 - The anti-viral medication approved to treat COVID-19 is now available on the Dutch market, the Dutch Association ...